Why are BioNTech shares down 4.3% today?

Traders Union
All News
Stocks
Biontech slides 4.38% to $86.73 today

Highlights

BioNTech posted third-quarter revenue of EUR 1.3 billion and a net profit of EUR 184.5 million on weaker COVID-19 vaccine demand.
The company entered a Phase 3 trial partnership with Gilead Sciences for a new combination treatment in metastatic triple-negative breast cancer.
Shares of BioNTech last traded at $86.73, under persistent seller pressure below major moving averages, with a projected five-day range of $84.22 to $89.24.

Lower vaccine demand and new trial partnership shape mixed sentiment

BioNTech reported third-quarter revenue of EUR 1.3 billion, reflecting lower COVID-19 vaccine demand, and posted a net profit of EUR 184.5 million with substantial cash reserves of EUR 16.2 billion. The company announced a Phase 3 clinical trial partnership with Gilead Sciences to test a new combination treatment for metastatic triple-negative breast cancer. Portfolio retrenchment and share buybacks, totaling 5 million shares since June, were also recorded, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, notes the persisting sell-off in BioNTech driven by weak technicals and waning vaccine revenue. He highlights the company's substantial cash reserves and strategic retrenchment but sees little immediate relief as shares remain under pressure and major moving averages act as resistance. The ongoing bearish momentum, coupled with negative technical indicators and recent lackluster price action, signals potential for further downside risk. Kharitonov emphasizes that sentiment remains fragile despite buybacks and pipeline news, as demand trends have not stabilized. "Downward momentum is likely to persist unless BioNTech regains investor confidence through tangible revenue growth beyond vaccines," he states.

Viktoras Karapetjanc, expert at Traders Union, focuses on BioNTech’s forward-looking strategies and strong liquidity. He views the Gilead partnership and broad clinical pipeline as significant drivers for future growth. Karapetjanc points to portfolio optimization and share buybacks as signals of management confidence. He believes current volatility offers strategic entry for long-term investors as the company pivots beyond COVID-19. "BioNTech’s bullish structure remains intact — further growth is expected as new treatments advance and market sentiment shifts," he affirms.

Jainam Mehta, market strategist, observes that BioNTech trades well below all key moving averages, a sign of entrenched short-term and intermediate weakness. He notes the volatility band between $84.22 and $89.24, framing a likely range-bound scenario unless resistance or support breaks. Mehta sees a tactical opportunity for contrarian traders if the stock rebounds above $87.5, but warns of fresh downside if $86.44 fails. "A break from consolidation could trigger sharp moves — managing risk around these precise levels is critical for active participants," he comments.

Broad bearish momentum as price stays below technical markers

BioNTech is trading below its 20-day, 50-day, and 200-day moving averages ($89.68, $95.68, and $96.82 respectively), underscoring ongoing weakness across all timeframes. The nearest resistance is at $87.5, with support at $86.44, while the position below all major moving averages and a bearish Ichimoku Kijun ($92.56) indicate a dominant bearish trend. Momentum indicators remain negative: the MACD signals a strong sell, the ADX points to a weak trend, and both the RSI and CCI are neutral. The Stochastic RSI is overbought, while the Bull/Bear Power (BBP) sits in positive territory at 2.32, highlighting brief intraday buyer strength amid a session dominated by sellers and 3.81% intraday volatility.

Earlier, analysts noted that BioNTech was under sustained selling pressure as the company faced clinical trial setbacks and lagging momentum indicators. The latest results reinforce this bearish trend, with downside risk now centered on a confirmed break below the $86.44 support level.

Source of Data: BNTX Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.